B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by NextCure

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Provides Year-End Clinical Pipeline Updates
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
Tickers NXTC
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease
From NextCure
Via GlobeNewswire
Tickers NXTC
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
From NextCure
Via GlobeNewswire
Tickers NXTC
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure to Present at the JMP Securities Life Sciences Conference
From NextCure
Via GlobeNewswire
Tickers NXTC
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
From NextCure
Via GlobeNewswire
Tickers NXTC
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.